Adjuvant chemotherapy for people with stage IB cancer is controversial, as clinical trials have not clearly demonstrated a survival benefit.
Adjuvantna hemoterapija kod osoba koje su u stadijumu raka IB je sporna, s obzirom da klinička ispitivanja nisu jasno pokazala korist za preživljavanje.